Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Solid Tumor | Review

PARP inhibitors in gastric cancer: beacon of hope

Authors: Yali Wang, Kun Zheng, Yongbiao Huang, Hua Xiong, Jinfang Su, Rui Chen, Yanmei Zou

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Defects in the DNA damage response (DDR) can lead to genome instability, producing mutations or aberrations that promote the development and progression of cancer. But it also confers such cells vulnerable to cell death when they inhibit DNA damage repair. Poly (ADP-ribose) polymerase (PARP) plays a central role in many cellular processes, including DNA repair, replication, and transcription. PARP induces the occurrence of poly (ADP-ribosylation) (PARylation) when DNA single strand breaks (SSB) occur. PARP and various proteins can interact directly or indirectly through PARylation to regulate DNA repair. Inhibitors that directly target PARP have been found to block the SSB repair pathway, triggering homologous recombination deficiency (HRD) cancers to form synthetic lethal concepts that represent an anticancer strategy. It has therefore been investigated in many cancer types for more effective anti-cancer strategies, including gastric cancer (GC). This review describes the antitumor mechanisms of PARP inhibitors (PARPis), and the preclinical and clinical progress of PARPis as monotherapy and combination therapy in GC.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRef

Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese gastric Cancer association (2001-2007). Gastric Cancer. 2018;21(1):144–54. https://doi.org/10.1007/s10120-017-0716-7.CrossRefPubMed

Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):Cd004064.PubMed

Padmanabhan N, Ushijima T, Tan P. How to stomach an epigenetic insult: the gastric cancer epigenome. Nat Rev Gastroenterol Hepatol. 2017;14(8):467–78. https://doi.org/10.1038/nrgastro.2017.53.CrossRefPubMed

Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–74. https://doi.org/10.1038/35077232.CrossRefPubMed

Powell SN, Bindra RS. Targeting the DNA damage response for cancer therapy. DNA Repair (Amst). 2009;8(9):1153–65.CrossRef

Pascal JM, Ellenberger T, et al. DNA Repair (Amst). 2015;32:10–6.CrossRef

Amé J-C, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays. 2004;26(8):882–93.CrossRef

Hoevenaar WHM, Janssen A, Quirindongo AI, Ma H, Klaasen SJ, Teixeira A, et al. Degree and site of chromosomal instability define its oncogenic potential. Nat Commun. 2020;11(1):1501. https://doi.org/10.1038/s41467-020-15279-9.CrossRefPubMedPubMedCentral

10.

Ceccaldi R, Rondinelli B, D'Andrea AD. Repair pathway choices and consequences at the double-Strand break. Trends Cell Biol. 2016;26(1):52–64. https://doi.org/10.1016/j.tcb.2015.07.009.CrossRefPubMed

11.

Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689–98. https://doi.org/10.1038/nrc1691.CrossRefPubMed

12.

Ashworth A. A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–90. https://doi.org/10.1200/JCO.2008.16.0812.CrossRefPubMed

13.

Palazzo L, Mikoč A, Ahel I. ADP-ribosylation: new facets of an ancient modification. Febs J. 2017;284(18):2932–46.CrossRef

14.

Lüscher B, Bütepage M, Eckei L, Krieg S, Verheugd P, Shilton BH. ADP-Ribosylation, a multifaceted posttranslational modification involved in the control of cell physiology in health and disease. Chem Rev. 2018;118(3):1092–136. https://doi.org/10.1021/acs.chemrev.7b00122.CrossRefPubMed

15.

Lin H, Caroll KS. Introduction: posttranslational protein modification. Chem Rev. 2018;118(3):887–8. https://doi.org/10.1021/acs.chemrev.7b00756.CrossRefPubMed

16.

Perina D, Mikoč A, Ahel J, Ćetković H, Žaja R, Ahel I. Distribution of protein poly (ADP-ribosyl) ation systems across all domains of life. DNA Repair (Amst). 2014;23:4–16.CrossRef

17.

Chang P, Coughlin M, Mitchison TJ. Tankyrase-1 polymerization of poly (ADP-ribose) is required for spindle structure and function. Nat Cell Biol. 2005;7(11):1133–9. https://doi.org/10.1038/ncb1322.CrossRefPubMed

18.

Ozaki Y, Matsui H, Asou H, Nagamachi A, Aki D, Honda H, et al. Poly-ADP ribosylation of Miki by tankyrase-1 promotes centrosome maturation. Mol Cell. 2012;47(5):694–706. https://doi.org/10.1016/j.molcel.2012.06.033.CrossRefPubMed

19.

Hassa PO, Haenni SS, Elser M, Hottiger MO. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev. 2006;70(3):789–829. https://doi.org/10.1128/MMBR.00040-05.CrossRefPubMedPubMedCentral

20.

Gupte R, Liu Z, Kraus WL. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev. 2017;31(2):101–26. https://doi.org/10.1101/gad.291518.116.CrossRefPubMedPubMedCentral

21.

Crawford K, Bonfiglio JJ, Mikoč A, Matic I, Ahel I. Specificity of reversible ADP-ribosylation and regulation of cellular processes. Crit Rev Biochem Mol Biol. 2018;53(1):64–82. https://doi.org/10.1080/10409238.2017.1394265.CrossRefPubMed

22.

Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13(7):411–24. https://doi.org/10.1038/nrm3376.CrossRefPubMed

23.

Vyas S, Matic I, Uchima L, Rood J, Zaja R, Hay RT, et al. Family-wide analysis of poly (ADP-ribose) polymerase activity. Nat Commun. 2014;5(1):4426. https://doi.org/10.1038/ncomms5426.CrossRefPubMed

24.

Hottiger MO, Hassa PO, Lüscher B, Schüler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010;35(4):208–19. https://doi.org/10.1016/j.tibs.2009.12.003.CrossRefPubMed

25.

De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012;84(2):137–46. https://doi.org/10.1016/j.bcp.2012.03.018.CrossRefPubMed

26.

Pazzaglia S, Pioli C. Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases. Cells. 2019;9(1). https://doi.org/10.3390/cells9010041.

27.

Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly (ADP-ribose) and PARP-1. Genes Dev. 2012;26(5):417–32. https://doi.org/10.1101/gad.183509.111.CrossRefPubMedPubMedCentral

28.

Robert I, Karicheva O, Reina San Martin B, Schreiber V, Dantzer F. Functional aspects of PARylation in induced and programmed DNA repair processes: preserving genome integrity and modulating physiological events. Mol Asp Med. 2013;34(6):1138–52. https://doi.org/10.1016/j.mam.2013.02.001.CrossRef

29.

Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293–301. https://doi.org/10.1038/nrc2812.CrossRefPubMedPubMedCentral

30.

Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in Cancer. J Natl Cancer Inst. 2018;110(7):704–13. https://doi.org/10.1093/jnci/djy085.CrossRefPubMed

31.

Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–8. https://doi.org/10.1038/nature08467.CrossRefPubMedPubMedCentral

32.

O'Connor MJ. Targeting the DNA damage response in Cancer. Mol Cell. 2015;60(4):547–60. https://doi.org/10.1016/j.molcel.2015.10.040.CrossRefPubMed

33.

Shibata A, Jeggo PA. DNA double-strand break repair in a cellular context. Clin Oncol (R Coll Radiol). 2014;26(5):243–9.CrossRef

34.

Ranjha L, Howard SM, Cejka P. Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes. Chromosoma. 2018;127(2):187–214. https://doi.org/10.1007/s00412-017-0658-1.CrossRefPubMed

35.

Scully R, Panday A, Elango R, Willis NA. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20(11):698–714. https://doi.org/10.1038/s41580-019-0152-0.CrossRefPubMedPubMedCentral

36.

Symington LS. Mechanism and regulation of DNA end resection in eukaryotes. Crit Rev Biochem Mol Biol. 2016;51(3):195–212. https://doi.org/10.3109/10409238.2016.1172552.CrossRefPubMedPubMedCentral

37.

Helleday T. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res. 2003;532(1–2):103–15. https://doi.org/10.1016/j.mrfmmm.2003.08.013.CrossRefPubMed

38.

Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 2008;18(1):27–47. https://doi.org/10.1038/cr.2008.8.CrossRefPubMed

39.

Ström CE, Johansson F, Uhlén M, Szigyarto CA, Erixon K, Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011;39(8):3166–75. https://doi.org/10.1093/nar/gkq1241.CrossRefPubMed

40.

Brem R. Hall J.XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res. 2005;33(8):2512–20. https://doi.org/10.1093/nar/gki543.CrossRefPubMedPubMedCentral

41.

Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res. 1996;24(22):4387–94. https://doi.org/10.1093/nar/24.22.4387.CrossRefPubMedPubMedCentral

42.

Leppard JB, Dong Z, Mackey ZB, Tomkinson AE. Physical and functional interaction between DNA ligase IIIalpha and poly (ADP-ribose) polymerase 1 in DNA single-strand break repair. Mol Cell Biol. 2003;23(16):5919–27. https://doi.org/10.1128/MCB.23.16.5919-5927.2003.CrossRefPubMedPubMedCentral

43.

Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34(21):6170–82. https://doi.org/10.1093/nar/gkl840.CrossRefPubMedPubMedCentral

44.

Langelier MF, Riccio AA, Pascal JM. PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. Nucleic Acids Res. 2014;42(12):7762–75.CrossRef

45.

Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2019;73:1–9. https://doi.org/10.1016/j.ctrv.2018.12.002.CrossRefPubMed

46.

Grundy GJ, Rulten SL, Arribas-Bosacoma R, Davidson K, Kozik Z, Oliver AW, et al. The Ku-binding motif is a conserved module for recruitment and stimulation of non-homologous end-joining proteins. Nat Commun. 2016;7(1):11242. https://doi.org/10.1038/ncomms11242.CrossRefPubMedPubMedCentral

47.

Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M, et al. DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity. Cell. 2018;173(4):972–988.e923.CrossRef

48.

Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387–93. https://doi.org/10.1016/j.molonc.2011.07.001.CrossRefPubMedPubMedCentral

49.

Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–8. https://doi.org/10.1126/science.aam7344.CrossRefPubMedPubMedCentral

50.

Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99. https://doi.org/10.1158/0008-5472.CAN-12-2753.CrossRefPubMedPubMedCentral

51.

D'Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018;71:172–6.CrossRef

52.

Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34(5–6):360–94. https://doi.org/10.1101/gad.334516.119.CrossRefPubMedPubMedCentral

53.

Iyer S, Suresh S, Guo D, Daman K, Chen JCJ, Liu P, et al. Precise therapeutic gene correction by a simple nuclease-induced double-stranded break. Nature. 2019;568(7753):561–5. https://doi.org/10.1038/s41586-019-1076-8.CrossRefPubMedPubMedCentral

54.

Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature. 2015;518(7538):258–62. https://doi.org/10.1038/nature14184.CrossRefPubMedPubMedCentral

55.

Ahrabi S, Sarkar S, Pfister SX, Pirovano G, Higgins GS, Porter AC, et al. A role for human homologous recombination factors in suppressing microhomology-mediated end joining. Nucleic Acids Res. 2016;44(12):5743–57. https://doi.org/10.1093/nar/gkw326.CrossRefPubMedPubMedCentral

56.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. https://doi.org/10.1038/nature03445.CrossRefPubMed

57.

O'Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet. 2017;18(10):613–23. https://doi.org/10.1038/nrg.2017.47.CrossRefPubMed

58.

Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Nat Rev Clin Oncol. 2018;15(9):564–76. https://doi.org/10.1038/s41571-018-0055-6.CrossRefPubMed

59.

Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32–40. https://doi.org/10.1093/annonc/mdt384.CrossRefPubMed

60.

Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27(8):1449–55. https://doi.org/10.1093/annonc/mdw142.CrossRefPubMed

61.

Perkhofer L, Schmitt A, Romero Carrasco MC, Ihle M, Hampp S, Ruess DA, et al. ATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damage. Cancer Res. 2017;77(20):5576–90. https://doi.org/10.1158/0008-5472.CAN-17-0634.CrossRefPubMed

62.

Caumanns JJ, Wisman GBA, Berns K, van der Zee AGJ, de Jong S. ARID1A mutant ovarian clear cell carcinoma: a clear target for synthetic lethal strategies. Biochim Biophys Acta Rev Cancer. 2018;1870(2):176–84. https://doi.org/10.1016/j.bbcan.2018.07.005.CrossRefPubMed

63.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15. https://doi.org/10.1158/0008-5472.CAN-06-0140.CrossRefPubMed

64.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian Cancer. N Engl J Med. 2016;375(22):2154–64. https://doi.org/10.1056/NEJMoa1611310.CrossRefPubMed

65.

Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79(2):311–9. https://doi.org/10.1158/0008-5472.CAN-18-1003.CrossRefPubMed

66.

Lightfoot M, Montemorano L, Bixel K. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development? Curr Oncol Rep. 2020;22(3):29.CrossRef

67.

Lin KY, Kraus WL. PARP Inhibitors for Cancer Therapy. Cell. 2017;169(2):183.CrossRef

68.

Bochum S, Berger S, Martens UM. Olaparib. Recent Results Cancer Res. 2018;211:217–33. https://doi.org/10.1007/978-3-319-91442-8_15.CrossRefPubMed

69.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636–48. https://doi.org/10.1016/S1470-2045(19)30029-4.CrossRefPubMed

70.

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61. https://doi.org/10.1016/S0140-6736(17)32440-6.CrossRefPubMedPubMedCentral

71.

Hoy SM. Talazoparib: First Global Approval. Drugs. 2018;78(18):1939–46. https://doi.org/10.1007/s40265-018-1026-z.CrossRefPubMed

72.

Koosha F, Neshasteh-Riz A, Takavar A, Eyvazzadeh N, Mazaheri Z, Eynali S, et al. The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids. Biochem Biophys Res Commun. 2017;491(4):1092–7. https://doi.org/10.1016/j.bbrc.2017.08.018.CrossRefPubMed

73.

Motta C, D'Angeli F, Scalia M, Satriano C, Barbagallo D, Naletova I, et al. PJ-34 inhibits PARP-1 expression and ERK phosphorylation in glioma-conditioned brain microvascular endothelial cells. Eur J Pharmacol. 2015;761:55–64. https://doi.org/10.1016/j.ejphar.2015.04.026.CrossRefPubMed

74.

Thorsell AG, Ekblad T, Karlberg T, Löw M, Pinto AF, Trésaugues L, et al. Structural basis for potency and promiscuity in poly (ADP-ribose) polymerase (PARP) and Tankyrase inhibitors. J Med Chem. 2017;60(4):1262–71. https://doi.org/10.1021/acs.jmedchem.6b00990.CrossRefPubMed

75.

Mizutani A, Yashiroda Y, Muramatsu Y, Yoshida H, Chikada T, Tsumura T, et al. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci. 2018;109(12):4003–14. https://doi.org/10.1111/cas.13805.CrossRefPubMedPubMedCentral

76.

Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer. 2001;84(1):106–12. https://doi.org/10.1054/bjoc.2000.1555.CrossRefPubMedPubMedCentral

77.

Meng X, Song W, Deng B, Xing Z, Zhang W. 3-aminobenzamide, one of poly (ADP-ribose)polymerase-1 inhibitors, rescuesapoptosisin rat models of spinal cord injury. Int J Clin Exp Pathol. 2015;8(10):12207–15.PubMedPubMedCentral

78.

Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004;96(1):56–67. https://doi.org/10.1093/jnci/djh005.CrossRefPubMed

79.

Cao R. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor. J Mol Model. 2016;22(4):74. https://doi.org/10.1007/s00894-016-2952-x.CrossRefPubMed

80.

Sharif-Askari B, Amrein L, Aloyz R, Panasci L. PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. Breast Cancer Res Treat. 2018;172(1):23–32. https://doi.org/10.1007/s10549-018-4888-6.CrossRefPubMed

81.

Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, et al. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. J Exp Clin Cancer Res. 2018;37(1):129. https://doi.org/10.1186/s13046-018-0790-7.CrossRefPubMedPubMedCentral

82.

Chen K, Yang D, Li X, Sun B, Song F, Cao W, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015;112(4):1107–12. https://doi.org/10.1073/pnas.1422640112.CrossRefPubMedPubMedCentral

83.

Sahasrabudhe R, Lott P, Bohorquez M, Toal T, Estrada AP, Suarez JJ, et al. Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer. Gastroenterology. 2017;152(5):983–986.e986.CrossRef

84.

Pyriochou A, Olah G, Deitch EA, Szabó C, Papapetropoulos A. Inhibition of angiogenesis by the poly (ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med. 2008;22(1):113–8.PubMed

85.

Lacal PM, Tentori L, Muzi A, Ruffini F, Dorio AS, Xu W, et al. Pharmacological inhibition of poly (ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. Int J Oncol. 2009;34(3):861–72. https://doi.org/10.3892/ijo_00000213.CrossRefPubMed

86.

Rajesh M, Mukhopadhyay P, Godlewski G, Bátkai S, Haskó G, Liaudet L, et al. Poly (ADP-ribose) polymerase inhibition decreases angiogenesis. Biochem Biophys Res Commun. 2006;350(4):1056–62. https://doi.org/10.1016/j.bbrc.2006.09.160.CrossRefPubMedPubMedCentral

87.

Zampieri M, Guastafierro T, Calabrese R, Ciccarone F, Bacalini MG, Reale A, et al. ADP-ribose polymers localized on Ctcf-Parp1-Dnmt1 complex prevent methylation of Ctcf target sites. Biochem J. 2012;441(2):645–52. https://doi.org/10.1042/BJ20111417.CrossRefPubMed

88.

Kim CG, Lee H, Gupta N, Ramachandran S, Kaushik I, Srivastava S, et al. Role of Forkhead box class O proteins in cancer progression and metastasis. Semin Cancer Biol. 2018;50:142–51. https://doi.org/10.1016/j.semcancer.2017.07.007.CrossRefPubMed

89.

Park SH, Jang KY, Kim MJ, Yoon S, Jo Y, Kwon SM, et al. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications. Oncotarget. 2015;6(42):44819–31. https://doi.org/10.18632/oncotarget.6264.CrossRefPubMedPubMedCentral

90.

Yang XB, Zhao JJ, Huang CY, Wang QJ, Pan K, Wang DD, et al. Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients. PLoS One. 2013;8(10):e78158.CrossRef

91.

Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees-Miller SP, et al. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle. 2014;13(13):2129–37. https://doi.org/10.4161/cc.29212.CrossRefPubMedPubMedCentral

92.

Min A, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, et al. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol Cancer Ther. 2013;12(6):865–77. https://doi.org/10.1158/1535-7163.MCT-12-0950.CrossRefPubMed

93.

Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. Oncologist. 2021;26(1):e164–72. https://doi.org/10.1002/onco.13551.

94.

Yang L, Yang G, Ding Y, Huang Y, Liu S, Zhou L, et al. Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. Oncol Rep. 2018;40(1):479–87. https://doi.org/10.3892/or.2018.6445.CrossRef

95.

Amin O, Beauchamp MC, Nader PA, Laskov I, Iqbal S, Philip CA, et al. Suppression of homologous recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. BMC Cancer. 2015;15(1):817. https://doi.org/10.1186/s12885-015-1803-y.CrossRefPubMedPubMedCentral

96.

Rasmussen RD, Gajjar MK, Jensen KE, Hamerlik P. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Mol Oncol. 2016;10(5):751–63. https://doi.org/10.1016/j.molonc.2015.12.014.CrossRefPubMedPubMedCentral

97.

Zhong L, Wang R, Wang Y, Peng S, Ma Y, Ding S, et al. Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. Neoplasia. 2020;22(9):365–75. https://doi.org/10.1016/j.neo.2020.06.001.CrossRefPubMedPubMedCentral

98.

Koustas E, Karamouzis MV, Sarantis P, Schizas D, Papavassiliou AG. Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models. J Cell Mol Med. 2020;24(18):10420–31. https://doi.org/10.1111/jcmm.15655.CrossRefPubMedPubMedCentral

99.

Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ, et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol. 2013;8(1):65. https://doi.org/10.1186/1748-717X-8-65.CrossRefPubMedPubMedCentral

100.

Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007;6(3):945–56. https://doi.org/10.1158/1535-7163.MCT-06-0552.CrossRefPubMed

101.

Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of Olaparib plus paclitaxel in patients with recurrent or metastatic gastric Cancer. J Clin Oncol. 2015;33(33):3858–65. https://doi.org/10.1200/JCO.2014.60.0320.CrossRefPubMed

102.

Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1637–51. https://doi.org/10.1016/S1470-2045(17)30682-4.CrossRef

103.

Smyth E. Missing a GOLDen opportunity in gastric cancer. Lancet Oncol. 2017;18(12):1561–3. https://doi.org/10.1016/S1470-2045(17)30719-2.CrossRefPubMed

104.

Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, et al. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. Br J Cancer. 2018;118(7):938–46. https://doi.org/10.1038/s41416-018-0003-3.CrossRefPubMedPubMedCentral

105.

Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 2005;65(24):11597–604.CrossRef

106.

Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019;20(9):1306–15. https://doi.org/10.1016/S1470-2045(19)30396-1.CrossRefPubMed

107.

Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M. Weissman SM.FDA approval of PARP inhibitors and the impact on genetic counseling and genetic testing practices. J Genet Couns. 2018;27(1):131–9. https://doi.org/10.1007/s10897-017-0130-7.CrossRefPubMed

108.

Lim JSJ, Tan DSP. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel). 2017;9(8). https://doi.org/10.3390/cancers9080109.

Title: PARP inhibitors in gastric cancer: beacon of hope
Authors: Yali Wang
Kun Zheng
Yongbiao Huang
Hua Xiong
Jinfang Su
Rui Chen
Yanmei Zou
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Solid Tumor
Gastric Cancer
Gastric Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02005-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma

Correction to: Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma

METTL3-mediated m6A mRNA modification of FBXW7 suppresses lung adenocarcinoma

ROS and TGFβ: from pancreatic tumour growth to metastasis

The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?

Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer